opening of asian centers and singapore plant

With opening of China centers, (as company has developed a Sirtex website for Chinese population), the Singapore plant will be able to supply Sir Spheres on a timely basis to the Chinese and Indian and Asian populations. Seems as if growth could exceed 100% in this region which is similar to European growth. US growth will get another surge as Sirtex has been making the US Journal of Oncology publications on a very positive basis for its clinical trials for Sir Spheres being used in many more indications.